Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

211 results about "Metabolic Marker" patented technology

Specific metabolic changes that characterize an organism's state of health or disease, or response to a particular therapeutic intervention, and helps make diagnosis more accurate or enable physicians to make diagnosis before symptoms appear and to track disease progression.

Sleeping peptide and differential metabolite detection method for caenorhabditis elegans

The embodiment of the invention discloses a sleep peptide and differential metabolite detection method for caenorhabditis elegans, belongs to the technical field of organism metabolism, and aims to research sleep-awakening key metabolite of caenorhabditis elegans and a regulation mechanism of the sleep-awakening key metabolite. According to the sleep peptide for caenorhabditis elegans, the sleep peptide is an F4 monomer as shown in SEQ ID NO: 1. Compared with the prior art, the sleep and awakening process of the caenorhabditis elegans under the intervention of the goat milk-derived sleep peptide is analyzed through a metabonomics technology, the key metabolite for regulating and controlling sleep and awakening is successfully screened out, and a core metabolic pathway related to the key metabolite is disclosed. The application also constructs a metabolite-pathway-target regulation framework, fills the blank of sleep research in the aspect of metabolic regulation, provides a scientific basis for a sleep intervention strategy based on metabolic regulation, and also lays a foundation for developing metabolic markers of sleep states in the future.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY +1

Metabolic marker, kit and application of metabolic marker in auxiliary diagnosis of schizophrenia

The invention provides a group of metabolic markers, a kit and application of the metabolic markers in auxiliary diagnosis of schizophrenia. The metabolic markers comprise arachidonic acid, palmitamide and lysophosphatidylcholine (LPC) (17: 0 / 0: 0). By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.
Owner:ZHUMADIAN SECOND PEOPLES HOSPITAL (ZHUMADIAN PSYCHIATRIC HOSPITAL)

Application of metabolic marker in preparation of product for monitoring heart failure and product

The metabolic marker can be used for early diagnosis of heart failure, has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result, provides a basis for clinical decision, provides a certain basis for subsequent fundamental research and clinical research, and has potential application and research values. The metabolic marker comprises one or more of 1-(4-nitrophenyl) piperidine, sphingolipid d19: 3 / 23: 0, phosphatidyl ethanolamine 16: 1e / 22: 5, phosphatidyl ethanolamine 16: 1e / 22: 6, sphingolipid d14: 0 / 22: 1, 3-phosphoglyceric acid, phosphatidylcholine 15: 0 / 20: 4, phosphatidylcholine o-16: 1 / 18: 0, phosphatidylcholine 14: 0e / 20: 1, phosphatidylcholine 17: 0 / 18: 5, betaine, phosphatidylcholine 15: 0 / 18: 2 and phosphatidylcholine 18: 5e / 20: 4.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Metabolic biomarker for predicting cardiovascular disease risk of senile subclinical hypothyroidism patient and application of metabolic biomarker

The invention relates to a metabolic biomarker for predicting the cardiovascular disease risk of a patient with senile subclinical hypothyroidism and application of the metabolic biomarker. The marker comprises inosine, arachidonic acid, arginine, phenylalanine and glycocholic acid. According to the method, metabolite information of each plasma sample in a research queue is obtained by establishing an elderly SCH and concurrent CVD crowd queue and detecting by adopting a high performance liquid chromatography-mass spectrometry technology, and a targeted metabolic content map is established. According to the matrix expression of the metabolic marker, in combination with clinical follow-up visit data, a model is constructed by using machine learning Lasso-cox, and a clinical prediction model of the CVD risk of the elderly SCH patient is constructed to guide precise diagnosis and treatment of the elderly SCH. The invention further provides a kit containing the diagnostic marker suitable for predicting the CVD risk of the elderly SCH, and the kit can be used for predicting the CVD risk of the elderly SCH.
Owner:NANJING GULOU HOSPITAL GRP SUQIAN HOSPITAL CO LTD

Metabolic marker combination for ovarian cancer diagnosis and application thereof

The invention provides a metabolic marker combination for ovarian cancer diagnosis and application thereof, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for ovarian cancer diagnosis. The metabolic marker combination comprises phosphatidylcholine 34: 4, threonic acid, phosphatidylcholine 32: 2, pyroglutamic acid, phosphatidylcholine 36: 6 and ceramide d38: 2. According to the metabolic marker combination, plasma samples of a healthy subject and an ovarian cancer patient are analyzed, a group of biomarkers with significant difference are screened from the plasma samples, and the metabolic marker combination is a non-invasive, non-invasive and high-accuracy metabolic marker combination for distinguishing the healthy subject and the ovarian cancer patient. The method can be used for constructing a diagnostic model for distinguishing healthy subjects from ovarian cancer patients. The metabolic marker combination disclosed by the invention can be used for improving the diagnosis and evaluation capability of ovarian cancer patients, so that early discovery, early diagnosis and early intervention can be realized clinically, and the survival rate of the ovarian cancer patients is improved.
Owner:HARBIN METANOTITIA INC

Metabolic marker composition for early diagnosis of cervical cancer as well as screening method and application of metabolic marker composition

The invention discloses a metabolic marker composition for early diagnosis of cervical cancer as well as a screening method and application of the metabolic marker composition. The metabolic marker composition for early diagnosis of cervical cancer comprises pyroglutamic acid, lysophosphatidylcholine 20: 3, phosphatidylcholine 32: 2 and pyruvic acid. The metabolic marker composition provided by the invention has relatively high sensitivity and specificity when being used for early-stage cervical cancer diagnosis, can realize accurate screening of early-stage cervical cancer, and provides important help for prevention of cervical cancer and reduction of morbidity. Meanwhile, when the metabolic marker composition is used for early-stage cervical cancer diagnosis, operation is easy, a sample is convenient to obtain, cost is low, invasion is avoided, a patient can receive detection more conveniently, rapidly and safely, and the metabolic marker composition is more suitable for large-scale population screening and regular tracking in areas with shortage of medical resources.
Owner:HARBIN METANOTITIA INC

Negative ion metabolism marker for thyroid-associated ophthalmopathy, product and application of negative ion metabolism marker

The invention discloses a negative ion metabolism marker for thyroid-associated ophthalmopathy, a product and application of the negative ion metabolism marker. The metabolic marker is prepared from any one or more of 7alpha, 17alpha-dimethyl-5beta-androstane-3 alpha, 17beta-diol, N, N-dimethyl phosphatidyl ethanolamine, 15 (S)-hydroxy eicosatrienoic acid and 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine, and the metabolic marker is prepared from any one or more of the following raw materials: 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine. The invention provides a kit which comprises a detection reagent for detecting the negative ion metabolism marker. The invention provides a computer program product for thyroid-related eye diseases. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV +1

Rapid detection method for bloodstream infection pathogenic bacteria based on rapid mass spectrometry technology

The invention discloses a rapid detection method for bloodstream infection pathogenic bacteria based on a rapid mass spectrometry technology, and belongs to the technical field of medical detection. Analyzing the metabolic gas of the blood flow infected pathogenic bacteria by using UVP-TOFMS to obtain a pathogenic bacteria metabolic profile spectrogram; preprocessing the obtained pathogenic bacterium metabolism profile spectrogram data; integrating the preprocessed pathogenic bacterium metabolism profile spectrogram data by using a stacking algorithm, and constructing a pathogenic bacterium identification model; evaluating the effectiveness of the pathogenic bacterium identification model on a training set and a test set through accuracy, precision, a confusion matrix and a subject operation curve; and comparing and screening characteristic metabolic markers of the pathogenic bacteria by combining the importance and significance of model characteristics, and indicating the types of the pathogenic bacteria. The method does not need sample pretreatment, is simple and convenient to operate, short in detection time (20 seconds per sample), high in accuracy and suitable for clinical popularization, and provides technical support for early diagnosis and treatment of bloodstream infection.
Owner:SICHUAN UNIV

Detection kit and detection method for juvenile depression marker

The invention belongs to the technical field of teenager depression marker detection, and particularly relates to a teenager depression marker detection kit and a teenager depression marker detection method, the kit comprises an extraction liquid, an internal standard substance, a quality control substance and a mobile phase additive, the internal standard substance comprises a stable isotope labeled metabolic marker, the quality control substance comprises a standard metabolic marker, and the mobile phase additive comprises a mobile phase. The detection method comprises the following steps: S1, dissolving an internal standard substance by using a methanol-containing aqueous solution to prepare an internal standard stock solution; s2, methanol is added into the internal standard stock solution for dilution, uniform mixing is performed, and an extraction working solution is prepared; s3, taking a quality control product / sample, adding an extraction working solution, carrying out oscillation incubation, centrifuging, and taking supernate as a to-be-detected sample; s4, the sample to be detected is detected through a liquid chromatograph-mass spectrometer, various biomarkers related to depression in the body of the teenager can be rapidly and accurately detected, and an objective and reliable basis is provided for early diagnosis and illness state evaluation of the depression of the teenager.
Owner:CHONGQING PUJI LIFE TECH CO LTD

Specific metabolism marker combination for diagnosing ovarian cancer and application thereof

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.
Owner:HARBIN METANOTITIA INC

Metabolic marker for auxiliary diagnosis of schizophrenia, construction method and application

InactiveCN119534874AHealth-index calculationMedical automated diagnosisLysophosphatidyl ethanolamineHydroxybutyric acid
The invention provides a metabolic marker for auxiliary diagnosis of schizophrenia, a construction method and application. Wherein the metabolic marker comprises lysophosphatidylcholine (LPC) (17: 0 / 0: 0), oleamide, lysophosphatidyl ethanolamine LysoPE (18: 0 / 0: 0), palmitamide, lysophosphatidyl ethanolamine LysoPE (0: 0 / 20: 4), lysophosphatidyl ethanolamine LysoPE (22: 6 / 0: 0), p-methylphenol sulfate, lactic acid, 3-hydroxybutyric acid, lysophosphatidyl ethanolamine LysoPE (18: 2 / 0: 0), lysophosphatidyl ethanolamine LysoPE (16: 0 / 0: 0) and sphingosine 1-phosphate. By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.
Owner:ZHUMADIAN SECOND PEOPLES HOSPITAL (ZHUMADIAN PSYCHIATRIC HOSPITAL)

Metabolic marker combination, detection kit and detection method thereof, and auxiliary diagnosis method for female prediabetes mellitus

The invention relates to the technical field of clinical medicine, in particular to a metabolic marker combination, a detection kit and a detection method thereof and an auxiliary diagnosis method for female prediabetes mellitus. The metabolic marker combination is composed of Cer, Cer d18: 0 / 16: 0, Cer d18: 1 / 18: 0, Cer d18: 1 / 20: 0, Cer d18: 0 / 22: 0, Cer d18: 1 / 24: 0 and Cer d18: 0 / 24: 0. According to the invention, a group of small molecule metabolites is preferably selected. The group of small molecule metabolites are bioactive metabolites which are closely related to insulin resistance, impaired glucose tolerance and chronic inflammation, and are related to pathogenesis of prediabetes mellitus. The metabolic marker combination and the total clinical indexes are comprehensively used for assisting in diagnosing the prediabetes occurrence risk, the effect is good, and the prediabetes diagnosis performance of female people is greatly improved.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

Metabolic marker for screening and evaluating lung cancer risk and application thereof

The invention discloses a metabolic marker for screening and evaluating the risk of lung cancer and application thereof, and belongs to the technical field of biological medicine, the metabolic marker is selected from amino acid, carbohydrate, cofactor and vitamin, energy metabolite, lipid, nucleotide, peptide and allobiomass, and the like. The kit particularly comprises a group consisting of 1-linoleoyl phosphatidyl ethanolamine, fibrinogen splitting peptide with a sequence of ADPSGEGDFXAEGGGVR, isovaleryl carnitine, oleic acid, 1-arachidonyl phosphatidylcholine, arachidonic acid, acetyl phosphoric acid, ergothioneine, isoleucine and metoprolol acid, and is used for preparing a detection product, such as a kit, for screening and evaluating the risk of lung cancer. Through accurate detection and analysis of metabolic markers, the accuracy and efficiency of early diagnosis of lung cancer can be improved, and a new scientific basis is provided for future lung cancer prevention, treatment and personalized medical treatment.
Owner:ZHONGSHAN HOSPITAL FUDAN UNIV

Plasma metabolic markers for early diagnosis or prediction of gestational diabetes and their applications

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.
Owner:PEKING UNION MEDICAL COLLEGE HOSPITAL

Metabolic marker for auxiliary diagnosis of schizophrenia, construction method and application

PendingCN121164482AComponent separationHealth-index calculationLysophosphatidyl ethanolamineHydroxybutyric acid
The invention provides a metabolic marker for auxiliary diagnosis of schizophrenia, a construction method and application. Wherein the metabolic marker comprises lysophosphatidylcholine (LPC) (17: 0 / 0: 0), oleamide, lysophosphatidyl ethanolamine LysoPE (18: 0 / 0: 0), palmitamide, lysophosphatidyl ethanolamine LysoPE (0: 0 / 20: 4), lysophosphatidyl ethanolamine LysoPE (22: 6 / 0: 0), p-methylphenol sulfate, lactic acid, 3-hydroxybutyric acid, lysophosphatidyl ethanolamine LysoPE (18: 2 / 0: 0), lysophosphatidyl ethanolamine LysoPE (16: 0 / 0: 0) and sphingosine 1-phosphate. By utilizing the metabolic marker, auxiliary diagnosis of schizophrenia can be rapidly and accurately completed in the early stage of disease attack.
Owner:ZHUMADIAN SECOND PEOPLES HOSPITAL (ZHUMADIAN PSYCHIATRIC HOSPITAL)

Polycystic ovarian syndrome pregnancy outcome diagnosis marker and application thereof

The invention relates to the field of biomarkers, and particularly provides a polycystic ovarian syndrome pregnancy outcome diagnosis marker and application thereof. According to the present invention, the endometrial targeting metabonomics research is adopted to screen the disease-related potential metabolic markers such as N-Acetylaspartic acid, Suberic acid and isoallolithocholic acid, and the three metabolites are subjected to quantitative detection so as to accurately predict the pregnancy outcome of the polycystic ovarian syndrome patient, such that the pregnancy outcome of the polycystic ovarian syndrome patient can be accurately predicted, and the prediction of the pregnancy outcome of the polycystic ovarian syndrome patient can be easily achieved, such that the disease-related potential metabolic markers such as N-Acetylaspartic acid, suberic acid and isoallolithocholic acid can be provided. A new path is provided for early intervention of the disease state to improve the pregnancy outcome, and a new drug target is provided for evaluation of the endometrial function of the polycystic ovarian syndrome.
Owner:PEKING UNIVERSITY THIRD HOSPITAL (THE THIRD CLINICAL MEDICAL SCHOOL OF PEKING UNIVERSITY)

Metabolic marker combination for colorectal cancer t staging evaluation and detection and staging discrimination method thereof

PendingCN122330433AMultivariate statisticsIndividualized treatment
This invention provides a combination of metabolic biomarkers for T-staging assessment of colorectal cancer, comprising four groups of metabolite combinations specifically distinguishing different T stages of colorectal cancer, each group containing 10 endogenous small molecule metabolites. This invention also provides detection methods and applications for the above-mentioned metabolic biomarker combinations. Furthermore, this invention provides a method for T-staging colorectal cancer for non-diagnostic and therapeutic purposes, as well as a combination of metabolic biomarkers related to the evolution of T-staging and tumor invasion depth in colorectal cancer. The advantages of this invention are: by combining iEESI-MS detection with multivariate statistics and machine learning, specific metabolic biomarkers related to T-staging of colorectal cancer are screened, a T-staging discrimination model is constructed, and objective, accurate, and rapid assessment of T-staging of colorectal cancer is achieved, providing molecular support for preoperative individualized treatment.
Owner:JINING UNIV

Feces metabolism marker for predicting spontaneous premature delivery based on UHPLC-MS (Ultra High Performance Liquid Chromatography-Mass Spectrometry) and application

The invention discloses an excrement metabolism marker for predicting spontaneous premature delivery based on UHPLC-MS (Ultra High Performance Liquid Chromatography-Mass Spectrometry) and application, and belongs to the technical field of biological medicines. According to the premature pregnant woman excrement metabolite specific biomarker and the application thereof, the premature pregnant woman excrement metabolite specific biomarker is screened out through a non-targeted metabonomics technology, and the marker is 1-hydroxyl vitamine d2, Mirtazapine n-oxide, Tetraethene glycol or a combination of the 1-hydroxyl vitamine d2, the Mirtazapine n-oxide and the Tetraethene glycol. A premature delivery prediction model established by using the marker is high in sensitivity and good in specificity, and a reference basis is provided for early prediction and accurate prevention of spontaneous premature delivery.
Owner:KUNMING MEDICAL UNIVERSITY

Use of phosphatidylinositol and phosphatidylglycerol as metabolic markers for prediction of intracranial atherosclerosis progression

The application relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting intracranial atherosclerosis progression, and belongs to the technical field of medical biological detection. In the scheme, single-sample MR analysis is carried out by combining RICAS cohort data with external database data, causal correlation between metabolites and ICAS is analyzed, and serum biomarkers phosphatidylinositol PI 18:0 / 22:6 and phosphatidylglycerol PG 18:1 / 18:2 for ICAS occurrence and development are screened out by combining characteristic metabolic changes of ICAS with causal correlation analysis. ICAS progression is collected through prospective follow-up of the RICAS cohort, the correlation between the serum biomarkers and the ICAS progression is established, and it is verified that the serum biomarkers have transformation application value and can be used as a new biomarker for early prediction of ICAS progression and derivation.
Owner:SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG PROVINCIAL HOSPITAL)

AAGN disease metabolism marker, kit and application of AAGN disease metabolism marker

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease metabolism marker, a kit and application of the AAGN disease metabolism marker. In the blood or urine metabolism marker, the blood metabolism marker is prepared from one or more of 6-methyl nicotinamide, hypo-sulphosarcosine, guanosine, allopurinol, 8-hydroxy-2 '-deoxyguanosine, triglyceride or lysophosphatidylcholine; the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl-leucyl-phenylalanine, alloandrosterone, enterodiphenol and p-coumarin, and the urine metabolism markers comprise one or more of D-malic acid, leucyl-alanyl-valine, N-hydroxymethyl nicotinamide, DL-tribulus terrestris alkali, isoxotrexate, 1, 3-dimethyluric acid, leucyl- The metabolic marker combination and the kit are used for evaluating the disease activity state of a patient suffering from ANCA-related glomerulonephritis (AAGN), and have good repeatability, stability and biological correlation.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Use of 5-oxoproline in the preparation of a product for diagnosing chemotherapy-induced cardiomyopathy

ActiveCN119310288BComponent separationDisease diagnosisSmall molecule metabolismChemo therapy
The application discloses that 5-oxoproline can be used as a biomarker for diagnosing chemotherapy-induced cardiomyopathy, and for the first time provides a blood metabolic marker for assisting in predicting and early diagnosing chemotherapy drug-induced cardiomyopathy, which has high accuracy and diagnostic reference value. By accurately determining the content of the small molecule metabolic marker 5-oxoproline in blood, the diagnosis of early myocardial injury induced by chemotherapy drugs will no longer completely rely on conventional non-specific myocardial injury markers and imaging methods, but will rely on the content change of metabolic products in the blood of patients as an objective index, thus advancing the time window for discovering subclinical myocardial injury, significantly improving the early diagnosis detection rate, simplifying the diagnosis process, providing an opportunity for early intervention, helping to prevent or reverse the further aggravation of chemotherapy-induced cardiomyopathy, and thus improving the overall survival prognosis of tumor patients.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE +1

Metabolic marker aldosterone for screening heat stress Hu sheep as well as screening method and application thereof

The invention discloses a metabolic marker aldosterone for screening heat stress Hu sheep as well as a screening method and application thereof, and belongs to the technical field of livestock serum markers. The metabolic marker for screening the heat stress Hu sheep is aldosterone; the screening method comprises the following steps: (1) taking blood of known heat-sensitive Hu sheep or heat-resistant Hu sheep as a standard test sample, taking blood of Hu sheep to be detected as a detection sample, and centrifuging to obtain a serum sample; (2) detecting the aldosterone concentration in the serum sample; and (3) calculating the aldosterone concentration average value of the standard test sample, taking the calculated aldosterone concentration critical value as a reference level, if the aldosterone concentration of the detection sample is higher than the reference level, determining that the detection sample is a heat-resistant Hu sheep, and if the aldosterone concentration of the detection sample is lower than the reference level, determining that the detection sample is a heat-sensitive Hu sheep. The aldosterone is used as the marker for detection, has the characteristics of high accuracy and high sensitivity, and can be directly used as an evaluation index for distinguishing the heat-sensitive Hu sheep from the heat-resistant Hu sheep.
Owner:GUANGXI UNIV

A method and system for embryo quality testing

This invention discloses a method and system for embryo quality detection, relating to the field of embryo detection technology, including the following steps: S1: fertilized embryos are continuously cultured in an in vitro culture system containing specific metabolic marker detection components, and continuous dynamic imaging of the embryos is performed to obtain a complete dynamic developmental image sequence; S2: the dynamic developmental image sequence is segmented, and temporal developmental features are captured, identifying key time points such as pronucleus appearance and disappearance, cleavage, and blastocyst formation, and generating a segmentation mask corresponding to each frame of the dynamic developmental image sequence; this invention achieves full-process time-difference imaging to capture the temporal features of embryonic development, without trauma or interference, avoiding subjective bias in static observation; by segmenting the dynamic developmental image sequence and capturing temporal developmental features, the segmentation accuracy is high and the anti-interference ability is strong.
Owner:SHENYANG SHENGWEI MEDICAL TECH CO LTD +1

Use of reagents for detecting metabolic markers in the preparation of sleep disorder screening or diagnosis products

The present invention provides the use of a reagent for detecting metabolite markers in the preparation of a sleep disorder screening or diagnostic product, and relates to the field of biomedicine. The metabolite marker is selected from one or more of triglyceride metabolites, phosphatidylcholine metabolites, cholesterol lipid metabolites, phosphatidylethanolamine metabolites, ceramide metabolites, amino acids, polypeptides and their analogs, benzoic acid and its derivatives, fatty acid metabolites, fatty acid ester metabolites, steroid and derivative metabolites, and other types of metabolites. The present invention discloses the risk metabolites of sleep disorders and studies the relationship between these risk metabolites and sleep disorder comorbidities. These risk metabolites can be used as markers for screening or diagnosing sleep disorders, and are used for screening or diagnosing sleep disorders, especially for the screening or diagnosis of sleep disorders affected by different comorbidities, and have good application prospects.
Owner:SICHUAN UNIV

Application and method of metabolic marker

The invention discloses application and a method of a metabolic marker. Comprising an application of the metabolic marker in preparing a medicine for detecting the effectiveness of liver cancer immunotherapy and a method for detecting the effect of liver cancer immunotherapy by using the metabolic marker. The metabolic marker with high specificity, universality and reliability is used as a marker, animal experiments prove that the specific inhibition of the metabolic marker can enhance the curative effect of liver cancer immunotherapy, and the metabolic marker has clinical transformation potential.
Owner:THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE

In-vitro detection or cell imaging method for N4-acetylcytosine (ac4C) RNA

The invention discloses an in-vitro detection or cell imaging method for N4-acetylcytosine (ac4C) RNA (Ribonucleic Acid), and belongs to the technical field of molecular biology and biological imaging. According to the method, ac4C RNA is marked through fluorine metabolism to generate F-ac4C RNA, an ac4C specific probe and an RNA sequence specific probe are introduced, and efficient and specific in-vitro detection and in-situ imaging of ac4C RNA loci of cells are realized by combining a signal amplification technology of rolling circle amplification reaction (RCA). The method is suitable for in-vitro detection and cell imaging of specific ac4C sites of multiple types of RNA (such as rRNA, mRNA, lncRNA and tRNA) and multiple types of cells. The invention is expected to provide a new way for revealing ac4C modified biological functions and mechanisms, and plays an important role in diagnosis and treatment of RNA related diseases.
Owner:ZHONGNAN HOSPITAL OF WUHAN UNIV

Application and products of metabolic markers in the preparation of products for monitoring PB neurotoxicity

Disclosed are the use of a metabolic marker in the preparation of a product for monitoring PB neurotoxicity and a product thereof, which can be used for the early diagnosis of PB neurotoxicity with high sensitivity, rapidity, convenience, and accurate and reliable results. The metabolic markers include LysoPE 20:4 / 0:0, creatine, SM d18:1 / 24:0, SM d18:0 / 24:1, LysoPC 18:0, palmitoyl sphingomyelin, phosphocholine, PC 14:0 / 22:1, creatinine, PC 18:3 / 16:0, SM d18:1 / 16:0, sphingosine, choline, LysoPC 18:1, L-carnitine, palmitic acid, PC 18:0 / 20:4, 3-hydroxy-2-octylglutaric acid, L-acetylcarnitine, LysoPC 20:4, LysoPC 16:0, and PC 20:1 / 14:1.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Application of metabolic marker in pulmonary fibrosis diagnosis or prognosis evaluation

The invention provides application of a metabolic marker in pulmonary fibrosis diagnosis or prognosis evaluation, and belongs to the technical field of biological medicine. Systematic analysis of metabonomics discovers that lipid metabolism of a patient suffering from pulmonary fibrosis is remarkably changed, downstream products Palmitoyl ethanolamide and 2-amino-1, 3, 4-octadecantool of lipid metabolism can be used as potential biomarkers for diagnosing pulmonary fibrosis, and objective quantitative indexes are provided for diagnosis and prognosis evaluation of pulmonary fibrosis. The invention proves that the Palmitoyl ethanolamide and the 2-amino-1, 3, 4-octadecantool are obviously related to the lung function injury degree and the concentration of the acute-stage blood inflammation marker of the pulmonary fibrosis patient, and the related characteristics prove that the Palmitoyl ethanolamide and the 2-amino-1, 3, 4-octadecantool can be used as the biomarker for evaluating the prognosis of the patient.
Owner:YICHANG CENT PEOPLES HOSPITAL

Method for improving LC / MS analysis sensitivity

The invention relates to the technical field of liquid chromatography / mass spectrometry analysis, and discloses a method for improving LC / MS analysis sensitivity, which is suitable for detecting trace lipid metabolites (containing isomeride) of a biological sample. The core technical scheme is as follows: a magnetic molecularly imprinted polymer-solid phase support liquid-liquid extraction secondary purification system is adopted to remove matrix impurities, a gradient mobile phase containing a composite additive is matched to optimize separation, and the detection specificity is improved by an ion mobility spectrometry-segmented selective ion monitoring combined mode; and a stable isotope internal standard is synchronously introduced to correct quantitative deviation. Experiments show that the LOD of the method is as low as 0.12-0.25 ng / mL, the matrix effect is smaller than or equal to 5%, the separation degree and the recovery rate are excellent, low-abundance metabolic marker differences can be accurately captured, and a support is provided for disease diagnosis and metabonomics research.
Owner:NINGBO HOSPITAL OF TRADITIONAL CHINESE MEDICINE